

Clerk of the House of Representatives
Legislative Resource Center
B-106 Cannon Building
Washington, DC 20515

Secretary of the Senate
Office of Public Records
232 Hart Building
Washington, DC 20510

SECRETARY OF THE SENATE
01 AUG 13 PM 12:1

LOBBYING REPORT

Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required to Complete This Page

| | | | |
|--|----------------------------------|---|------------------------------------|
| 1. Registrant Name Clark & Weinstock | | | |
| 2. Registrant Address <input type="checkbox"/> Check if different than previously reported Address 1775 I Street NW, Ste 700 City Washington, State/Zip (or Country) DC 20006 | | | |
| 3. Principal Place of Business (if different from line 2) City New York, State/Zip (or Country) NY 10017 | | | |
| 4. Contact Name Lisa Simpson | Telephone 202-261-4025 | E-mail (optional) lisa@cwdc.com | 5. Senate ID # 9443--595 |
| 7. Client Name <input type="checkbox"/> Self PhRMA | | | 6. House ID # 316-98054 |

TYPE OF REPORT 8. Year 2001 Midyear (January 1-June 30) **OR** Year End (July 1-December 31)

9. Check if this filing amends a previously filed version of this report

10. Check if this is a Termination Report >> Termination Date _____

11. No Lobbying

INCOME OR EXPENSES - Complete Either Line 12 OR Line 13

| 12. Lobbying Firms | 13. Organizations |
|--|---|
| INCOME relating to lobbying activities for this reporting period was: Less than \$10,000 <input type="checkbox"/> \$10,000 or more <input checked="" type="checkbox"/> >> \$ <u>\$120,000.00</u> Income (nearest \$20,000) | EXPENSES relating to lobbying activities for this reporting period were: Less than \$10,000 <input type="checkbox"/> \$10,000 or more <input type="checkbox"/> >> \$ _____ Expenses (nearest \$20,000) |
| Provide a good faith estimate, rounded to the nearest \$20,000 of all lobbying related income from the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client). | 14. REPORTING METHOD. Check box to indicate the accounting method. See instructions for description of options: <input type="checkbox"/> Method A. Reporting amounts using LDA definition <input type="checkbox"/> Method B. Reporting amounts under section 6033(l) of the Internal Revenue Code <input type="checkbox"/> Method C. Reporting amounts under section 162(e) of the Internal Revenue Code |

Signature _____ Date 8/9/01



Registrant Name: Clark & Weinstock

Client Name: PhRMA

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. **Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.**

15. General issue area code HCR (one per page)

16. Specific Lobbying issues
see attached page

17. House(s) of Congress and Federal agencies contacted Check if None
**Department of Health & Human Services
Executive Office of the President
House of Representatives
Senate**

18. Name of each individual who acted as a lobbyist in this issue area

| Name | Covered Official Position (if applicable) |
|--------------------------|---|
| Bieron, Brian | Policy Director, House Rules Committee |
| Fazio, Vic | |
| Gribbin, Dave | |
| Kutler, Ed | |
| Mathews, Jim | |
| Morrison, Timothy | Associate Director, Presidential Personnel |
| Stach, Deirdre | |

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

Signature _____ Date 8/9/01

Registrant Name: Clark & Weinstock

Client Name: PhRMA

| Item | Description | Data |
|------|-----------------|---|
| 16 | Lobbying Issues | <p>Lobbied for Medicare reform and to provide prescription drug coverage for seniors:</p> <p>H.R. 2330, Agriculture, Rural Development, Food and Drug Administration, a related agencies Appropriations Act 2002</p> <p>H. AMDT. 140, Brown amendment, makes available an additional 2.5 million dollars for the Food and Drug Administration Office of Generic Drugs</p> <p>H. AMDT. 141, Brown amendment, allocates 5 million dollars to carry out the FDA's antibiotic resistance plan</p> <p>H. AMDT. 147, Sanders amendment, amendment sought to prohibit use of fur for enforcement of Section 801 (d) (1) of the Federal Food, Drug and Cosmetic Act</p> <p>H. AMDT. 150, Gutknecht amendment, prohibits use of funds in the bill for the purpose of preventing an individual who is not in the business of importing prescription drugs, from importing drugs that (1) appear to be FDA approved do not appear to be narcotic drugs, and (3) appear to be manufactured, prepared, propagated, compounded, or processed in an establishment pursuant to the Federal Food, Drug and Cosmetic Act</p> <p>H. AMDT. 163, Brown amendment, increases the funding by one million dollar responsibilities of the FDA with respect to abbreviated applications for the approval of new drugs</p> <p>H. AMDT. 164, Allen amendment, to prohibit use of funds for approval of new drug applications without disclosure of the cost of research and development of new drug and what portion of that cost is made up with public funding</p> <p>Intellectual Property and Patent issues including the following:</p> <p>S. 812, Greater Access to Affordable Pharmaceuticals Act of 2001, to amend the federal Food, Drug and Cosmetic Act to provide greater access to affordable pharmaceuticals</p> <p>S. 1229, To amend the Federal Food, Drug, and Cosmetic Act to permit individuals to import prescription drugs in limited circumstances; worked on the Dorgan and Wellstone amendments dealing with intellectual property issues</p> |



Registrant Name: Clark & Weinstock

Client Name: PhRMA

| Item | Description | Data |
|------|---------------------------|--|
| 18a | Lobbyist Name | Stuart, Sandi |
| 18b | Covered Official Position | |
| 18c | New Lobbyist | No |
| 18a | Lobbyist Name | Urban, Anne |
| 18b | Covered Official Position | Legislative Director, Sen. Robert Kerrey |
| 18c | New Lobbyist | Yes |
| 18a | Lobbyist Name | Weber, Vin |
| 18b | Covered Official Position | |
| 18c | New Lobbyist | No |



Registrant Name: Clark & Weinstock

Client Name: PhRMA

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. **Using a separate page for each code**, provide information as requested. Attach additional page(s) as needed.

15. General issue area code MED (one per page)

16. Specific Lobbying issues
See attached page.

17. House(s) of Congress and Federal agencies contacted Check if None
Department of Health & Human Services
Executive Office of the President
House of Representatives
Senate

18. Name of each individual who acted as a lobbyist in this issue area

| Name | Covered Official Position (if applicable) |
|--------------------------|---|
| Bieron, Brian | Policy Director, House Rules Committee |
| Fazio, Vic | |
| Gribbin, Dave | |
| Kutler, Ed | |
| Mathews, Jim | |
| Morrison, Timothy | Associate Director, Presidential Personnel |
| Stach, Deirdre | |

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

Signature _____ Date 8/9/01



Registrant Name: Clark & Weinstock

Client Name: PhRMA

| Item | Description | Data |
|------|-----------------|---|
| 16 | Lobbying Issues | <p>Lobbied for Medicare reform and to provide prescription drug coverage for seniors:</p> <p>H.R. 2330, Agriculture, Rural Development, Food and Drug Administration, a related agencies Appropriations Act 2002</p> <p>H. AMDT. 140, Brown amendment, makes available an additional 2.5 million dollars for the Food and Drug Administration Office of Generic Drugs</p> <p>H. AMDT. 141, Brown amendment, allocates 5 million dollars to carry out the FDA's antibiotic resistance plan</p> <p>H. AMDT. 147, Sanders amendment, amendment sought to prohibit use of funds for enforcement of Section 801 (d) (1) of the Federal Food, Drug and Cosmetic Act</p> <p>H. AMDT. 150, Gutknecht amendment, prohibits use of funds in the bill for the purpose of preventing an individual who is not in the business of importing prescription drugs, from importing drugs that (1) appear to be FDA approved do not appear to be narcotic drugs, and (3) appear to be manufactured, prepared, propagated, compounded, or processed in an establishment pursuant to the Federal Food, Drug and Cosmetic Act</p> <p>H. AMDT. 163, Brown amendment, increases the funding by one million dollar responsibilities of the FDA with respect to abbreviated applications for the approval of new drugs</p> <p>H. AMDT. 164, Allen amendment, to prohibit use of funds for approval of new drug applications without disclosure of the cost of research and development of new drug and what portion of that cost is made up with public funding</p> <p>Intellectual Property and Patent issues including the following:</p> <p>S. 812, Greater Access to Affordable Pharmaceuticals Act of 2001, to amend the federal Food, Drug and Cosmetic Act to provide greater access to affordable pharmaceuticals</p> <p>S. 1229, To amend the Federal Food, Drug, and Cosmetic Act to permit individuals to import prescription drugs in limited circumstances; worked on the Dorgan and Wellstone amendments dealing with intellectual property issues</p> |



Registrant Name: **Clark & Weinstock**

Client Name: **PhRMA**

| Item | Description | Data |
|------|---------------------------|--|
| 18a | Lobbyist Name | Stuart, Sandi |
| 18b | Covered Official Position | |
| 18c | New Lobbyist | No |
| 18a | Lobbyist Name | Urban, Anne |
| 18b | Covered Official Position | Legislative Director, Sen. Robert Kerrey |
| 18c | New Lobbyist | Yes |
| 18a | Lobbyist Name | Weber, Vin |
| 18b | Covered Official Position | |
| 18c | New Lobbyist | No |



Registrant Name: Clark & Weinstock

Client Name: PhRMA

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. **Using a separate page for each code**, provide information as requested. Attach additional page(s) as needed.

15. General issue area code MMM (one per page)

16. Specific Lobbying issues
see attached page

17. House(s) of Congress and Federal agencies contacted Check if None
House of Representatives
Senate

18. Name of each individual who acted as a lobbyist in this issue area

| Name | Covered Official Position (if applicable) |
|--------------------------|---|
| Bieron, Brian | Policy Director, House Rules Committee |
| Fazio, Vic | |
| Gribbin, Dave | |
| Kutler, Ed | |
| Mathews, Jim | |
| Morrison, Timothy | Associate Director, Presidential Personnel |
| Stach, Deirdre | |

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

Signature  Date 8/9/01



Registrant Name: **Clark & Weinstock**

Client Name: **PhRMA**

| Item | Description | Data |
|------|-----------------|--|
| 16 | Lobbying Issues | <p>Lobbied for Medicare reform and to provide prescription drug coverage for seniors:</p> <p>H.R. 2330, Agriculture, Rural Development, Food and Drug Administration, and related agencies Appropriations Act 2002</p> <p>H. AMDT. 140, Brown amendment, makes available an additional 2.5 million dollars for the Food and Drug Administration Office of Generic Drugs</p> <p>H. AMDT. 141, Brown amendment, allocates 5 million dollars to carry out the FDA's antibiotic resistance plan</p> <p>H. AMDT. 147, Sanders amendment, amendment sought to prohibit use of funds for enforcement of Section 801 (d) (1) of the Federal Food, Drug and Cosmetic Act</p> <p>H. AMDT. 150, Gutknecht amendment, prohibits use of funds in the bill for the purpose of preventing an individual who is not in the business of importing prescription drugs, from importing drugs that (1) appear to be FDA approved, (2) do not appear to be narcotic drugs, and (3) appear to be manufactured, prepared, propagated, compounded, or processed in an establishment pursuant to the Federal Food, Drug and Cosmetic Act</p> <p>H. AMDT. 163, Brown amendment, increases the funding by one million dollars for the responsibilities of the FDA with respect to abbreviated applications for the approval of new drugs</p> <p>H. AMDT. 164, Allen amendment, to prohibit use of funds for approval of new drug applications without disclosure of the cost of research and development of new drug and what portion of that cost is made up with public funding</p> |



Registrant Name: Clark & Weinstock

Client Name: PhRMA

| Item | Description | Data |
|------|---------------------------|--|
| 18a | Lobbyist Name | Stuart, Sandi |
| 18b | Covered Official Position | |
| 18c | New Lobbyist | No |
| 18a | Lobbyist Name | Urban, Anne |
| 18b | Covered Official Position | Legislative Director, Sen. Robert Kerrey |
| 18c | New Lobbyist | Yes |
| 18a | Lobbyist Name | Weber, Vin |
| 18b | Covered Official Position | |
| 18c | New Lobbyist | No |

